Chemotherapy alone for patients with stageⅡ/Ⅲrectal cancer undergoing radical surgery. Al Gizawy SM,Essa HH,Ahmed BM,et al. The Oncologist . 2015AlGizawy SM, Essa HH, Ahmed BM. Chemo- therapy alone for patients with stage II/III rectal cancer undergoing radical surgery. Oncologist 2015; ...
Recently, the National Surgical Adjuvant Study of Colorectal Cancer in Japan, a randomised controlled trial of oral uracil–tegafur (UFT) adjuvant therapy for stage III rectal cancer, showed remarkable survival gains, compared with surgery alone. To eval
Adjuvant chemotherapy (n = 204) was not significantly associated with the risk of recurrence (HR 0.94 (0.66-1.32)) or cancer specific death (HR 0.73 (0.50-1.04)), but those patients had a significantly higher overall survival because of less non-cancer related death (HR0.40 (0.30-0.53))....
The reported 3-year DFS of CRT for patients with locally advanced rectal cancer is 71.6–75.9%21,22,23, which is equivalent to the results of the present study. However, CRT has been recently shown to increase perioperative complications, such as local infections and anastomotic leakage6. ...
Induction chemotherapy has been shown to improve survival of patients with stage III A/N2 (T1–3, N2, M0) non-small cell lung cancer (NSCLC), followed by resection, but the benefits of neoadjuvant radiotherapy still remain controversial. PubMed, Embase, and Cochrane library databases were searc...
In colo- rectal cancer, pemetrexed treatment alone increased T cell activation in a mouse model, and induced ICD [55]. As a result, pemetrexed is a highly interesting candidate for combination treatment with radiotherapy and im- munotherapy due to the increased activity and infiltra- tion of T...
Identifying the Optimal Radiation Dose in Locally Advanced Non-Small-cell Lung Cancer Treated With Definitive Radiotherapy Without Concurrent Chemotherapy Introduction:The optimal radiation dose for locally advanced non-small-cell lung cancer (NSCLC) is not known for patients who receive sequential chemorad...
(Edmonton) Research from the University of Alberta provides new insight into treatment patterns for people with stage two and three rectal cancer—information that ultimately will help physicians improve care strategies for patients provincewide.
Guideline questions:1) Does the use of postoperative, adjuvant radiotherapy or chemotherapy, alone or in combination, improve survival rates among patients with completely resected, pathologically confirmed stage II or IIIA non-small-cell lung cancer (NSCLC)? 2) Does the use of radiotherapy reduce ...
(interquartile range (IQR): 18–43) days, and that between surgery and the postoperative blood test was 41 (IQR: 33–55) days. Preoperative adjuvant chemoradiotherapy was performed in three patients with rectal cancer. Postoperative adjuvant chemoradiotherapy was performed only in one case because ...